查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2035324

生物標記檢測市場預測至2034年—按檢測類型、生物標記類型、技術、疾病領域、應用、最終用戶和地區分類的全球分析

Biomarker Testing Market Forecasts to 2034 - Global Analysis By Test Type, Biomarker Type, Technology, Disease Area, Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球生物標記檢測市場規模將達到 224 億美元，並在預測期內以 13.3% 的複合年成長率成長，到 2034 年將達到 610 億美元。

生物標記檢測是指測量和分析基因、蛋白質和代謝物等生物指標，以評估正常的生物過程、疾病進展或治療反應。該市場在精準醫療的發展中發揮核心作用，為腫瘤學、神經病學和自體免疫疾病等領域的個人化治療策略提供了支持。隨著伴隨診斷和液態生物檢體技術的日益普及，生物標記檢測的臨床效用價值不斷擴大；同時，次世代定序和質譜技術的進步也提高了檢測的準確性、處理能力和在常規患者照護中的可及性。

全球癌症發生率不斷上升，以及對個人化癌症治療的需求日益成長

全球癌症負擔日益加重，推動了對生物標記檢測的空前需求，以指導標靶治療和免疫療法。腫瘤生物標記和基因組檢測使臨床醫生能夠識別特定的突變，例如 EGFR、BRCA 和 PD-L1 表達，從而實現精準用藥，提高患者生存率並減少不必要的化療。隨著癌症藥物研發越來越依賴基於生物標記的患者分層，監管機構要求在新治療方法上市的同時核准伴隨診斷。診斷技術的進步與治療方法的創新之間的這種協同作用確保了市場的持續成長，使生物標記檢測成為現代癌症治療過程中不可或缺的一部分。

高昂的費用和保險報銷的限制

儘管臨床應用價值顯著，但許多經濟障礙阻礙了先進生物標記檢測在許多醫療系統中的廣泛應用。全面的基因組分析和多參數檢測可能需要花費每位患者數百甚至數千美元，這對於資源匱乏的地區和未投保者來說難以負擔。公共和私人保險公司之間報銷政策的不一致，為臨床檢查室和醫院帶來了不確定性，阻礙了對檢測基礎設施的投資。此外，保險覆蓋範圍往往落後於技術進步，迫使患者承擔新的生物標記檢測費用。這些經濟限制對低收入地區的影響尤其嚴重，加劇了醫療保健方面的不平等，並阻礙了市場充分發揮其潛力。

液態生物檢體在癌症早期檢測的應用日益廣泛

微創液態生物檢體技術無需組織取樣，即可為篩檢、早期診斷和治療監測開闢廣闊前景。透過檢測血液中的循環腫瘤DNA、外泌體或腫瘤來源的血小板，這些檢測方法能夠持續監測治療反應並早期識別抗藥性突變。利用單次血液樣本早期檢測多種癌症的新應用有望徹底改變大規模篩檢項目，在症狀出現之前即可發現惡性腫瘤。隨著檢測靈敏度的提高和成本的降低，液態生物檢體有望成為侵入性組織切片檢查的補充，並在某些情況下取代後者，從而顯著擴大預防醫學中生物標記檢測的潛在市場。

監管複雜性與數據解讀挑戰

在全球監管環境片段化的背景下，市場協調和偵測商業化面臨嚴峻挑戰。被歸類為實驗室自建檢測（LDT）的生物標記檢測與體外診斷醫療器材受不同的監管，這給開發商帶來了合規性的不確定性。同時，高通量平台產生的大量基因組和蛋白質組數據給現有的生物資訊基礎設施帶來了巨大壓力，並導致不同檢查室間解讀結果的差異。報告標準的不一致以及缺乏普遍接受的變異分類指南增加了誤診和不當治療決策的風險。這些挑戰會削弱臨床醫師的信心，並延緩其應用，尤其對於缺乏在不同族群中可靠臨床檢驗的新型生物標記物更是如此。

新冠疫情的影響：

疫情擾亂了生物標記檢測市場，但也帶來了意想不到的加速發展。檢查室資源一度被轉移到新冠病毒檢測，導致非緊急癌症診斷和擇期手術延遲。然而，這場危機也展現了分散式和居家檢測模式的有效性，並推動了遠端檢體採集和數位健康技術在生物標記工作流程中的應用創新。人們對感染疾病標記的認知不斷提高，也促進了相關技術向其他治療領域的轉移。從長遠來看，疫情凸顯了快速、準確的診斷基礎設施的重要性，並促使各國政府加大對基因組監測能力的投資。如今，這些能力正被全球重新應用於腫瘤學和罕見疾病檢測計畫。

在預測期內，腫瘤生物標記檢測領域預計將佔據最大的市場佔有率。

預計在預測期內，腫瘤生物標記檢測領域將佔據最大的市場佔有率，這主要得益於精準醫療中腫瘤應用的持續主導地位。腫瘤生物標記，包括蛋白質過度表現、基因突變和循環性腫瘤細胞（CTC），幾乎貫穿癌症管理的各個階段，從風險評估和早期檢測到治療方法選擇和復發監測，都至關重要。隨著標靶治療和免疫療法的日益普及，伴隨診斷檢測在識別合格的患者群體方面的重要性也日益凸顯。目前，已有超過200種癌症和數千種相關生物標記正在研究中，該領域持續吸引最高的研發投入和商業活動，預計在整個預測期內將保持其主導地位。

在預測期內，生物標記領域預計將呈現最高的複合年成長率。

在預測期內，預測性生物標記領域預計將呈現最高的成長率。這反映了藥物研發和臨床實踐中，治療前患者分層的趨勢正在加速發展。與預測疾病結局而不考慮治療方法的預後標記不同，預測性生物標記能夠直接識別最有可能對特定治療方法反應的患者，從而最大限度地減少不利事件和醫療資源的浪費。依賴PD-L1和MSI評分的免疫療法以及需要進行BRCA檢測的PARP抑制劑的興起，清晰地展現了這一趨勢。隨著基於生物標記的臨床試驗在藥物研發管線中被優先考慮，以及監管機構建議將生物標記與伴隨診斷相結合進行開發，預測性生物標記檢測的成長速度將超過其他任何類別，從而改變多個疾病領域的治療模式。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其先進的醫療基礎設施、較高的人均醫療支出以及雄厚的公私科研經費。美國在透過FDA伴隨診斷途徑核准新型生物標記檢測方面處於主導地位，主要的診斷公司和臨床實驗室也總部設在該地區。學術機構和當地癌症治療機構廣泛採用次世代定序，加上聯邦醫療保險和私人保險公司的優惠報銷政策，確保了北美市場持續領先地位。此外，病患權益倡導組織和精準醫療舉措也在推動對尖端生物標記檢測服務的持續需求。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於龐大的患者群體、不斷上漲的醫療成本以及診斷能力的快速現代化。中國、印度、日本和韓國等國的癌症發生率正在激增，而中產階級也越來越容易獲得先進的醫療技術。政府主導的精準醫療舉措，例如中國的“精準醫療計劃”，正在大力投資基因組基礎設施和人力資源發展。在本地生產檢測試劑和平台降低成本的同時，國際診斷公司正在與區域實驗室建立策略合作夥伴關係。隨著監管協調的推進和人們對基於生物標記的療法的認知不斷提高，亞太地區正在成為生物標記檢測領域中成長最快的市場。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球生物標記檢測市場：依檢測類型分類

  • 腫瘤生物標記檢測
  • 基因組檢測
  • 蛋白質體學檢測
  • 代謝體學學檢測
  • 基於影像的生物標記檢測
  • 其他測試類型

第6章 全球生物標記檢測市場：依生物標記類型分類

  • 預測性生物標記
  • 預後生物標記
  • 安全生物標記
  • 動態物標誌物
  • 替代生物標記

第7章 全球生物標記檢測市場：依技術分類

  • 聚合酵素鏈鎖反應（PCR）
  • 次世代定序（NGS）
  • 免疫檢測
  • 質譜分析
  • 微陣列技術
  • 其他技術

第8章 全球生物標記檢測市場：依疾病領域分類

  • 腫瘤學
  • 心血管疾病
  • 神經系統疾病
  • 感染疾病
  • 代謝性疾病
  • 其他疾病領域

第9章 全球生物標記檢測市場：依應用領域分類

  • 臨床診斷
  • 藥物發現與開發
  • 個人化醫療
  • 臨床研究
  • 其他用途

第10章 全球生物標記檢測市場：依最終用戶分類

  • 醫院和診所
  • 診斷檢查室
  • 製藥和生物技術公司
  • 學術研究機構
  • 其他最終用戶

第11章 全球生物標記檢測市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第14章：公司簡介

  • Thermo Fisher Scientific Inc.
  • F Hoffmann La Roche Ltd
  • Abbott Laboratories
  • Danaher Corporation
  • Bio Rad Laboratories Inc.
  • Qiagen NV
  • Agilent Technologies Inc.
  • PerkinElmer Inc.
  • Siemens Healthineers AG
  • Illumina Inc.
  • Merck KGaA
  • Waters Corporation
  • Myriad Genetics Inc.
  • Guardant Health Inc.
  • Exact Sciences Corporation
  • NeoGenomics Inc.
Product Code: SMRC35651

According to Stratistics MRC, the Global Biomarker Testing Market is accounted for $22.4 billion in 2026 and is expected to reach $61.0 billion by 2034 growing at a CAGR of 13.3% during the forecast period. Biomarker testing involves the measurement and analysis of biological indicators such as genes, proteins, or metabolites to assess normal biological processes, disease progression, or therapeutic responses. This market is central to the evolution of precision medicine, enabling tailored treatment strategies across oncology, neurology, and autoimmune disorders. The increasing adoption of companion diagnostics and liquid biopsy techniques is expanding the clinical utility of biomarker tests, while technological advancements in next-generation sequencing and mass spectrometry are enhancing testing accuracy, throughput, and accessibility for routine patient care.

Market Dynamics:

Driver:

Rising global cancer incidence and demand for personalized oncology

The escalating burden of cancer worldwide is fueling unprecedented demand for biomarker testing to guide targeted therapies and immunotherapies. Tumor biomarker and genomic testing enable clinicians to identify specific mutations, such as EGFR, BRCA, or PD-L1 expression, allowing for precise drug selection that improves survival outcomes while reducing unnecessary chemotherapy exposure. As oncology drug development increasingly relies on biomarker-driven patient stratification, regulatory agencies are mandating companion diagnostic approvals alongside novel therapies. This symbiotic relationship between diagnostic advancement and therapeutic innovation ensures sustained market expansion, with biomarker testing becoming non-negotiable in modern cancer care pathways.

Restraint:

High costs and reimbursement limitations

Despite clinical benefits, significant financial barriers hinder widespread adoption of advanced biomarker testing across many healthcare systems. Comprehensive genomic profiling and multi-analyte tests can cost hundreds to thousands of dollars per patient, placing them beyond reach in resource-limited settings or for uninsured populations. Inconsistent reimbursement policies across public and private payers create uncertainty for clinical laboratories and hospitals, discouraging investment in testing infrastructure. Additionally, coverage often lags behind test innovation, leaving patients to shoulder expenses for emerging biomarkers. These economic constraints disproportionately affect lower-income regions, widening healthcare disparities and slowing the market's full potential.

Opportunity:

Expansion of liquid biopsy for early cancer detection

Minimally invasive liquid biopsy technologies are unlocking vast opportunities for screening, early diagnosis, and treatment monitoring without tissue sampling. By detecting circulating tumor DNA, exosomes, or tumor-educated platelets in blood, these tests enable serial monitoring of treatment response and early identification of resistance mutations. Emerging applications in multi-cancer early detection from a single blood draw promise to revolutionize population screening programs, catching malignancies before symptoms appear. As assay sensitivity improves and costs decrease, liquid biopsy is expected to complement-and in some cases replace-invasive tissue biopsies, dramatically expanding the addressable market for biomarker testing across preventive medicine.

Threat:

Regulatory complexity and data interpretation challenges

Navigating fragmented global regulatory landscapes poses serious threats to market harmonization and test commercialization. Biomarker tests classified as laboratory-developed tests face different oversight compared to in vitro diagnostics, creating compliance uncertainty for developers. Simultaneously, the vast volume of genomic and proteomic data generated by high-throughput platforms strains existing bioinformatics infrastructure, leading to interpretation variability across laboratories. Inconsistent reporting standards and lack of universally accepted variant classification guidelines risk misdiagnosis or inappropriate treatment decisions. These challenges may erode clinician confidence and delay adoption, especially for novel biomarkers lacking robust clinical validation in diverse populations.

Covid-19 Impact:

The pandemic created both disruptions and unexpected accelerations for biomarker testing markets. Laboratory resources were temporarily diverted to COVID-19 testing, delaying non-urgent cancer diagnostics and elective procedure volumes. However, the crisis validated decentralized and at-home testing models, spurring innovations in remote sample collection and digital health integration for biomarker workflows. Increased awareness of infectious disease biomarkers also stimulated technology transfer to other therapeutic areas. Long-term, the pandemic reinforced the value of rapid, accurate diagnostic infrastructure, prompting government investments in genomic surveillance capabilities that are now being repurposed for oncology and rare disease testing programs worldwide.

The Tumor Biomarker Testing segment is expected to be the largest during the forecast period

The Tumor Biomarker Testing segment is expected to account for the largest market share during the forecast period, driven by the persistent dominance of oncology applications in precision medicine. Tumor biomarkers, including protein overexpression, gene mutations, and circulating tumor cells, are integral to nearly every stage of cancer management-from risk assessment and early detection to treatment selection and recurrence monitoring. The proliferation of targeted therapies and immunotherapies has created a dependency on companion diagnostic tests that identify eligible patient populations. With over 200 cancer types and thousands of associated biomarkers under investigation, this segment continues to attract the highest research investment and commercial activity, ensuring its leadership throughout the forecast timeline.

The Predictive Biomarkers segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Predictive Biomarkers segment is predicted to witness the highest growth rate, reflecting the accelerating shift toward pre-treatment patient stratification in drug development and clinical practice. Unlike prognostic markers that forecast disease outcome regardless of therapy, predictive biomarkers directly inform which patients are most likely to respond to a specific intervention, minimizing adverse events and healthcare waste. The rise of immunotherapies reliant on PD-L1 and MSI scoring, as well as PARP inhibitors requiring BRCA testing, exemplifies this trend. As pharmaceutical pipelines prioritize biomarker-anchored trials and regulatory bodies encourage codevelopment of drugs with companion diagnostics, predictive biomarker testing will expand faster than any other category, reshaping therapeutic paradigms across multiple disease areas.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, underpinned by advanced healthcare infrastructure, high per-capita healthcare spending, and strong private and public research funding. The United States leads in regulatory approvals for novel biomarker tests through the FDA's companion diagnostic pathway, while major diagnostic companies and clinical laboratories are headquartered in the region. Widespread adoption of next-generation sequencing in both academic and community oncology settings, combined with favorable reimbursement policies from Medicare and private insurers, ensures sustained market leadership. Additionally, patient advocacy groups and precision medicine initiatives drive continuous demand for cutting-edge biomarker testing services.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by large patient populations, rising healthcare expenditures, and rapid modernization of diagnostic capabilities. Countries including China, India, Japan, and South Korea are witnessing a surge in cancer incidence alongside expanding middle-class access to advanced medical technologies. Government-led precision medicine initiatives, such as China's "Precision Medicine Plan," are investing heavily in genomic infrastructure and training. Local manufacturing of testing reagents and platforms is reducing costs, while international diagnostic companies are forming strategic partnerships with regional laboratories. As regulatory harmonization progresses and awareness of biomarker-guided therapy grows, Asia Pacific emerges as the fastest-growing market for biomarker testing.

Key players in the market

Some of the key players in Biomarker Testing Market include Thermo Fisher Scientific Inc., F Hoffmann La Roche Ltd, Abbott Laboratories, Danaher Corporation, Bio Rad Laboratories Inc., Qiagen NV, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers AG, Illumina Inc., Merck KGaA, Waters Corporation, Myriad Genetics Inc., Guardant Health Inc., Exact Sciences Corporation and NeoGenomics Inc.

Key Developments:

In April 2026, Abbott received the AACR Cancer Prevention Research Award for its DETECT-A study, the first large prospective interventional trial of a blood-based multi-cancer early detection test in a real-world setting.

In March 2026, Agilent showcased expanded biomarker capabilities at the USCAP Annual Meeting, featuring a new PD-L1 indication for epithelial ovarian, fallopian tube, and primary peritoneal carcinoma to guide immunotherapy.

In March 2026, Illumina expanded its collaboration with Labcorp to increase access to precision oncology, focusing on the co-commercialization of FDA-authorized liquid biopsy and solid tumor profiling kits (TruSight Oncology Comprehensive).

Test Types Covered:

  • Tumor Biomarker Testing
  • Genomic Testing
  • Proteomic Testing
  • Metabolomic Testing
  • Imaging Biomarker Testing
  • Other Test Types

Biomarker Types Covered:

  • Predictive Biomarkers
  • Prognostic Biomarkers
  • Safety Biomarkers
  • Pharmacodynamic Biomarkers
  • Surrogate Biomarkers

Technologies Covered:

  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunoassays
  • Mass Spectrometry
  • Microarray Technology
  • Other Technologies

Disease Areas Covered:

  • Oncology
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious Diseases
  • Metabolic Disorders
  • Other Disease Areas

Applications Covered:

  • Clinical Diagnostics
  • Drug Discovery & Development
  • Personalized Medicine
  • Clinical Research
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Biomarker Testing Market, By Test Type

  • 5.1 Tumor Biomarker Testing
  • 5.2 Genomic Testing
  • 5.3 Proteomic Testing
  • 5.4 Metabolomic Testing
  • 5.5 Imaging Biomarker Testing
  • 5.6 Other Test Types

6 Global Biomarker Testing Market, By Biomarker Type

  • 6.1 Predictive Biomarkers
  • 6.2 Prognostic Biomarkers
  • 6.3 Safety Biomarkers
  • 6.4 Pharmacodynamic Biomarkers
  • 6.5 Surrogate Biomarkers

7 Global Biomarker Testing Market, By Technology

  • 7.1 Polymerase Chain Reaction (PCR)
  • 7.2 Next-Generation Sequencing (NGS)
  • 7.3 Immunoassays
  • 7.4 Mass Spectrometry
  • 7.5 Microarray Technology
  • 7.6 Other Technologies

8 Global Biomarker Testing Market, By Disease Area

  • 8.1 Oncology
  • 8.2 Cardiovascular Diseases
  • 8.3 Neurological Disorders
  • 8.4 Infectious Diseases
  • 8.5 Metabolic Disorders
  • 8.6 Other Disease Areas

9 Global Biomarker Testing Market, By Application

  • 9.1 Clinical Diagnostics
  • 9.2 Drug Discovery & Development
  • 9.3 Personalized Medicine
  • 9.4 Clinical Research
  • 9.5 Other Applications

10 Global Biomarker Testing Market, By End User

  • 10.1 Hospitals & Clinics
  • 10.2 Diagnostic Laboratories
  • 10.3 Pharmaceutical & Biotechnology Companies
  • 10.4 Academic & Research Institutes
  • 10.5 Other End Users

11 Global Biomarker Testing Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Thermo Fisher Scientific Inc.
  • 14.2 F Hoffmann La Roche Ltd
  • 14.3 Abbott Laboratories
  • 14.4 Danaher Corporation
  • 14.5 Bio Rad Laboratories Inc.
  • 14.6 Qiagen NV
  • 14.7 Agilent Technologies Inc.
  • 14.8 PerkinElmer Inc.
  • 14.9 Siemens Healthineers AG
  • 14.10 Illumina Inc.
  • 14.11 Merck KGaA
  • 14.12 Waters Corporation
  • 14.13 Myriad Genetics Inc.
  • 14.14 Guardant Health Inc.
  • 14.15 Exact Sciences Corporation
  • 14.16 NeoGenomics Inc.

List of Tables

  • Table 1 Global Biomarker Testing Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Biomarker Testing Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 3 Global Biomarker Testing Market Outlook, By Tumor Biomarker Testing (2023-2034) ($MN)
  • Table 4 Global Biomarker Testing Market Outlook, By Genomic Testing (2023-2034) ($MN)
  • Table 5 Global Biomarker Testing Market Outlook, By Proteomic Testing (2023-2034) ($MN)
  • Table 6 Global Biomarker Testing Market Outlook, By Metabolomic Testing (2023-2034) ($MN)
  • Table 7 Global Biomarker Testing Market Outlook, By Imaging Biomarker Testing (2023-2034) ($MN)
  • Table 8 Global Biomarker Testing Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 9 Global Biomarker Testing Market Outlook, By Biomarker Type (2023-2034) ($MN)
  • Table 10 Global Biomarker Testing Market Outlook, By Predictive Biomarkers (2023-2034) ($MN)
  • Table 11 Global Biomarker Testing Market Outlook, By Prognostic Biomarkers (2023-2034) ($MN)
  • Table 12 Global Biomarker Testing Market Outlook, By Safety Biomarkers (2023-2034) ($MN)
  • Table 13 Global Biomarker Testing Market Outlook, By Pharmacodynamic Biomarkers (2023-2034) ($MN)
  • Table 14 Global Biomarker Testing Market Outlook, By Surrogate Biomarkers (2023-2034) ($MN)
  • Table 15 Global Biomarker Testing Market Outlook, By Technology (2023-2034) ($MN)
  • Table 16 Global Biomarker Testing Market Outlook, By Polymerase Chain Reaction (PCR) (2023-2034) ($MN)
  • Table 17 Global Biomarker Testing Market Outlook, By Next-Generation Sequencing (NGS) (2023-2034) ($MN)
  • Table 18 Global Biomarker Testing Market Outlook, By Immunoassays (2023-2034) ($MN)
  • Table 19 Global Biomarker Testing Market Outlook, By Mass Spectrometry (2023-2034) ($MN)
  • Table 20 Global Biomarker Testing Market Outlook, By Microarray Technology (2023-2034) ($MN)
  • Table 21 Global Biomarker Testing Market Outlook, By Other Technologies (2023-2034) ($MN)
  • Table 22 Global Biomarker Testing Market Outlook, By Disease Area (2023-2034) ($MN)
  • Table 23 Global Biomarker Testing Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 24 Global Biomarker Testing Market Outlook, By Cardiovascular Diseases (2023-2034) ($MN)
  • Table 25 Global Biomarker Testing Market Outlook, By Neurological Disorders (2023-2034) ($MN)
  • Table 26 Global Biomarker Testing Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 27 Global Biomarker Testing Market Outlook, By Metabolic Disorders (2023-2034) ($MN)
  • Table 28 Global Biomarker Testing Market Outlook, By Other Disease Areas (2023-2034) ($MN)
  • Table 29 Global Biomarker Testing Market Outlook, By Application (2023-2034) ($MN)
  • Table 30 Global Biomarker Testing Market Outlook, By Clinical Diagnostics (2023-2034) ($MN)
  • Table 31 Global Biomarker Testing Market Outlook, By Drug Discovery & Development (2023-2034) ($MN)
  • Table 32 Global Biomarker Testing Market Outlook, By Personalized Medicine (2023-2034) ($MN)
  • Table 33 Global Biomarker Testing Market Outlook, By Clinical Research (2023-2034) ($MN)
  • Table 34 Global Biomarker Testing Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 35 Global Biomarker Testing Market Outlook, By End User (2023-2034) ($MN)
  • Table 36 Global Biomarker Testing Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 37 Global Biomarker Testing Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 38 Global Biomarker Testing Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 39 Global Biomarker Testing Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
  • Table 40 Global Biomarker Testing Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.